Benefits of supplemental oxygen on exercise capacity and dyspnea in IPF patients
Not Applicable
- Conditions
- idiopathic pulmonary fibrosis
- Registration Number
- JPRN-UMIN000025256
- Lead Sponsor
- Tosei General Hospital
- Brief Summary
Supplemental oxygen increased endurance time than supplemental placebo air(oxygen: 546.5 sec vs placebo air: 427.8 sec, p<0.05). Dyspnea and leg fatigue at isotime were improved significantly by supplemental oxygen.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 106
Inclusion Criteria
Not provided
Exclusion Criteria
severe comorbid illnesses, collagen vascular diseases, and the need for long-term oxygen therapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method endurance time of constant work-rate test
- Secondary Outcome Measures
Name Time Method dyspnea, leg fatigue (Borg scale) (before and every 1 minute and end of oxygen therapy)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does supplemental oxygen improve exercise capacity in IPF patients via mitochondrial function or oxidative stress reduction?
What is the comparative effectiveness of supplemental oxygen versus standard antifibrotic therapies in IPF for dyspnea and endurance?
What are the primary clinical endpoints in JPRN-UMIN000025256 supplemental oxygen trial for IPF patients?
Which biomarkers predict response to supplemental oxygen in idiopathic pulmonary fibrosis during exercise testing?
What are the adverse event profiles of long-term supplemental oxygen in IPF patients and management strategies?